| Level: | PhD |
| Tuition: | Full coverage |
| Deadline: | Jan 27, 2027 |
| Duration max: | 99 months |
| Level: | PhD |
| Tuition: | Full coverage |
| Deadline: | Jan 27, 2027 |
| Duration max: | 99 months |
Acute myeloid leukaemia (AML) is the second most common leukaemia, accounting for 32% of all leukaemia in diagnosed in adults. AML is an aggressive malignancy of the bone marrow, as is characterized by uncontrolled proliferation of undifferentiated myeloid lineage cells and dismal survival rates, particularly among older patients. AML presents a significant clinical burden to the NHS because the intensive chemotherapy regimens necessary to bring the disease under control often result in hospitalisation due to side effects. There is therefore distinct clinical need of new therapies that will more specifically target the tumour with minimal toxicity.
Funded by the MRC for 3.5yrs, including a minimum of 3 months working within the industry partner. Funding will cover UK tuition fees and an enhanced stipend (around £17,785) only. We aim to support the most outstanding applicants from outside the UK. We are able to offer a limited number of bursaries that will enable full studentships to be awarded to international applicants. These full studentships will only be awarded to exceptional quality candidates, due to the competitive nature of this scheme.
Open to students worldwide